Skip to Content

Research

LORELEI

Research

Research

Clinicaltrial.gov identifier:
NCT02273973
Status:
Closed
Scenario:
Neoadjuvant
Tumour subtype:
HR+
Phase:
Phase II
Drug/Intervention:
GDC-0032

Addition of the PI3K/Akt pathway selective inhibitor taselisib to neoadjuvant letrozole in postmenopausal women with HR+ early stage breast cancer

A phase II Randomized, double-blind study of neoadjuvant Letrozole Plus GDC-0032 versus Letrozole plus placebo in postmenopausal women with  HER-positive/HER2- negative, early stage Breast Cancer.

Sponsors

Genentech, Inc

Collaborators

Breast International Group
SOLTI
Austrian Breast and Colorectal Cancer Group

Principal investigators

Cristina Saura, MD

Vall d’Hebrón Institut d’Oncologia, Barcelona

Evandro de Azambuja, MD, PhD

Medical Director at the BREAST Data Centre at the Jules Bordet Institute

X
Utilizamos cookies propias y de terceros para mejorar nuestros servicios mediante el análisis de sus hábitos de navegación. Puede cambiar la configuración u obtener más información aquí.